13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001131399
Total reported value
$602.2M
$602.2M
15 檔
109.9%
According to the latest 13F quarterly dataset, GSK plc managed an equity portfolio of $602.2M at the end of Q4 2025, spanning 15 distinct U.S. exchange-listed positions.
During Q4 2025, GSK plc's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including WVE, CRSP, BNTX) accounted for 109.9% of total reported equity market value during Q4 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | WVE | Wave Life Sciences Ltd. | Stock-Other | 38.82% | -4.48% | — | |
| 2 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 21.14% | +3.60% | — | |
| 3 | BNTX | Biontech Se-adr | Stock-Other | 10.60% | +0.55% | — | |
| 4 | VIR | Vir Biotechnology Inc | Stock-Other | 6.45% | +1.68% | — | |
| 5 | LYEL | Lyell Immunopharma Inc | Stock-Other | 5.83% | -1.53% | — | |
| 6 | IDYA | Ideaya Biosciences Inc | Stock-Other | 5.77% | +0.84% | — | |
| 7 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.71% | +1.08% | — | |
| 8 | SPRO | Spero Therapeutics Inc | Stock-Other | 2.68% | -0.22% | — | |
| 9 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 2.53% | -1.20% | — | |
| 10 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 1.36% | -0.10% | — | |
| 11 | CVRX | Cvrx Inc | Stock-Other | 0.90% | -0.73% | — | |
| 12 | NKTX | Nkarta Inc | Stock-Other | 0.73% | +0.37% | — | |
| 13 | RGNX | Regenxbio Inc | Stock-Other | 0.49% | +0.16% | — | |
| 14 | SENS | Senseonics Holdings Inc | Stock-Other | 0.01% | — | — | |
| 15 | HBIOUSD | Harvard Bioscience Inc | Stock-Other | — | — | — |
According to official SEC Form 13F filings, GSK plc reported a total U.S. public equity portfolio value of $602.2M across 15 disclosed positions in Q4 2025.
During Q4 2025, GSK plc's top holdings by market value included WVE (38.8%)、CRSP (21.1%)、BNTX (10.6%). The largest single position, WVE, represented 38.8% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In Q4 2025, GSK plc made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.